C/EBPα regulates CRL4Cdt2-mediated degradation of p21 in response to UVB-induced DNA damage to control the G1/S checkpoint

被引:23
|
作者
Hall, Jonathan R. [1 ]
Bereman, Michael S. [1 ,2 ]
Nepomuceno, Angelito I. [3 ]
Thompson, Elizabeth A. [1 ]
Muddiman, David C. [2 ,3 ]
Smart, Robert C. [1 ,2 ]
机构
[1] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA
[2] N Carolina State Univ, Ctr Human Hlth & Environm, Raleigh, NC 27695 USA
[3] N Carolina State Univ, Dept Chem, WM Keck FT ICR Mass Spectrometry Lab, Raleigh, NC 27695 USA
关键词
C/EBP alpha; CRL4(Cdt2); G(1)/S DNA damage checkpoint; keratinocytes; p21; CYCLIN-DEPENDENT KINASES; CELL NUCLEAR ANTIGEN; S-PHASE; UBIQUITIN LIGASE; SKIN-CANCER; IN-VIVO; EXPRESSION; PCNA; INHIBITOR; GROWTH;
D O I
10.4161/15384101.2014.962957
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The bZIP transcription factor, C/EBP is highly inducible by UVB and other DNA damaging agents in keratinocytes. C/EBP-deficient keratinocytes fail to undergo cell cycle arrest in G(1) in response to UVB-induced DNA damage and mice lacking epidermal C/EBP are highly susceptible to UVB-induced skin cancer. The mechanism through which C/EBP regulates the cell cycle checkpoint in response to DNA damage is unknown. Here we report untreated C/EBP-deficient keratinocytes have normal levels of the cyclin-dependent kinase inhibitor, p21, however, UVB-treated C/EBP-deficient keratinocytes fail to up-regulate nuclear p21 protein levels despite normal up-regulation of Cdkn1a mRNA levels. UVB-treated C/EBP-deficient keratinocytes displayed a 4-fold decrease in nuclear p21 protein half-life due to the increased proteasomal degradation of p21 via the E3 ubiquitin ligase CRL4(Cdt2). Cdt2 is the substrate recognition subunit of CRL4(Cdt2) and Cdt2 mRNA and protein levels were up-regulated in UVB-treated C/EBP-deficient keratinocytes. Knockdown of Cdt2 restored p21 protein levels in UVB-treated C/EBP-deficient keratinocytes. Lastly, the failure to accumulate p21 in response to UVB in C/EBP-deficient keratinocytes resulted in decreased p21 interactions with critical cell cycle regulatory proteins, increased CDK2 activity, and inappropriate entry into S-phase. These findings reveal C/EBP regulates G(1)/S cell cycle arrest in response to DNA damage via the control of CRL4(Cdt2) mediated degradation of p21.
引用
收藏
页码:3602 / 3610
页数:9
相关论文
共 7 条
  • [1] Gcn2p regulates a G1/S cell cycle checkpoint in response to DNA damage
    Menacho-Marquez, Mauricio
    Perez-Valle, Jorge
    Arino, Joaquin
    Gadea, Jose
    Murguia, Jose R.
    [J]. CELL CYCLE, 2007, 6 (18) : 2302 - 2305
  • [2] p21 inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint
    Satyanarayana, Ande
    Hilton, Mary Beth
    Kaldis, Philipp
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2008, 19 (01) : 65 - 77
  • [3] MEKK1-Dependent Activation of the CRL4 Complex Is Important for DNA Damage-Induced Degradation of p21 and DDB2 and Cell Survival
    Bacher, Susanne
    Stekman, Hilda
    Farah, Carla M.
    Karger, Annika
    Kracht, Michael
    Schmitz, M. Lienhard
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2021, 41 (10)
  • [4] Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated
    McKenzie, PP
    Guichard, SM
    Middlemas, DS
    Ashmun, RA
    Danks, MK
    Harris, LC
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 (12) : 4199 - 4207
  • [5] Response of human mammary epithelial cells to DNA damage induced by 4-hydroxyequilenin:: Lack of p53-mediated G1 arrest
    Cuendet, Muriel
    Bolton, Judy L.
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2006, 161 (03) : 271 - 278
  • [6] Intact regulation of G1/S transition renders esophageal squamous cell carcinomas sensitive to PI3Kα inhibitors by blocking SKP2-mediated p21 degradation.
    Wang, Yuxiang
    Zhang, Xu
    Zhang, Xi
    Shen, Yanyan
    Ma, Qingyang
    Qiao, Yuemei
    Wang, Yi
    Yang, Biyu
    Xu, Lan
    Ge, Gaoxiang
    Hu, Landian
    Kong, Xiangyin
    Yang, Chunhao
    Ding, Jian
    Chen, Yi
    Meng, Linghua
    [J]. CANCER RESEARCH, 2022, 82 (12)